About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs

  • Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months
  • nAAVigation platform will be launched at the Cell & Gene Meeting on the Mesa

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform which streamlines the pathway to GMP AAV vector manufacturing without the need for significant process development. The nAAVigation platform has the capability to reduce a program’s timeline to GMP for viral vector gene therapy developers by 55 percent, translating to fewer than eight (8) months compared to traditional manufacturing workflows.

Charles River’s nAAVigation approach is based on a proprietary high-productivity HEK293 suspension cell line, which is amenable to clients’ scale-up and serotype needs. nAAVigation utilizes an optimized single-use upstream approach coupled with robust downstream purification processes, enabling client AAV programs to scale up to 500L in suspension. The nAAVigation platform accelerates time to clinic by leveraging established development processes, on-hand materials, templated documents, and 100 percent qualified, in-house analytics.

Meeting on the Mesa

Charles River will launch the nAAVigation platform approach and will highlight its benefits during a reception on October 12, during Cell and Gene Meeting on the Mesa, in Carlsbad, CA.

Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services will present at the Reception in the Command Post Meeting Room:

  • nAAVigationTM Vector Platform: Accelerating Your AAV Pathway to GMP and Clinic - Wednesday, October 12, 5:00pm – 8:00 pm PST

In addition, Nicholas Ostrout, PhD, Senior Advisor, Cell and Gene Therapy Corporate Strategy, will present in Aviara Salon A:

  • The Future of CDMO Networks in Cell and Gene Therapy - Wednesday, October 12, 7:45am – 8:45am PST

Daniel Smith, PhD, Executive Director, Global Cell and Gene Therapy Portfolio will present in UBC Ballroom:

  • New Business Models for Manufacturing Investment - Wednesday, October 12, 3:15pm – 4:15pm PST

Join Charles River for three days of partnering and industry updates on clinical trial design, alternative payment models, scale-up and supply chain platforms for advanced therapies, and more.

Viral Vector CDMO Services

With over 20 years of viral vector CDMO expertise and a validated platform process with a proven track record, Charles River has standardized protocols for cell culture, transfection, and downstream purification. These high-yield, optimized methods increase speed to clinical manufacturing by reducing process development time and costs while ensuring the highest quality production.

nAAVigation builds on Charles River’s industry-leading viral vector CDMO capabilities with established processes for AAV production and purification, and testing expertise.

Expanding its comprehensive cell and gene therapy portfolio to span viral vector, plasmid DNA, and cell therapy production, through the acquisitions of Vigene Biosciences, Cobra Biologics, and Cognate Bioservices in 2021, the Company offers end-to-end support and supply chain simplification for advanced therapy (ATMP) developers.

Approved Quotes

  • “The launch of the nAAVigation Vector Platform process is the latest in a series of portfolio enhancements aimed at supporting our cell and gene therapy clients from early target identification through clinical-stage manufacturing. By increasing speed and efficiency for viral vector production, nAAVigation will help accomplish our ultimate goal of delivering safe, effective therapies to patients faster.” – Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River
  • “The significant turnaround time reduction for viral vector therapy developers utilizing nAAVigation combined with Charles River’s established development process, standard, on-hand materials, templated documents, and in-house analytics will enhance our clients’ experiences.”– Professor Daniel Smith, Executive Director Global Cell and Gene Therapy Portfolio, Charles River

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor:

Todd Spencer

Corporate Vice President,

Investor Relations

781.222.6455

todd.spencer@crl.com

Media:

Amy Cianciaruso

Corporate Vice President,

Chief Communications Officer

781.222.6168

amy.cianciaruso@crl.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.